InterveXion Therapeutics

About:

InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical company

Top Investors: National Institutes of Health, National Institute on Drug Abuse (NIDA)

Description:

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Total Funding Amount:

$52.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Little Rock, Arkansas, United States

Founded Date:

2004-01-01

Founders:

Ralph Henry

Number of Employees:

51-100

Last Funding Date:

2021-11-01

IPO Status:

Private

Industries: